Navigation Links
Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
Date:5/24/2011

EAST HANOVER, N.J., May 25, 2011 /PRNewswire/ -- Novartis announced today results of two pivotal Phase III trials in patients with severe gouty arthritis, showing that ACZ885 (canakinumab) provided superior pain relief and reduced the risk of suffering new attacks by up to 68% compared to an injectable steroid (triamcinolone acetonide, TA) used to treat gouty arthritis attacks(1,2). ACZ885 is an investigational fully human monoclonal antibody.

The studies involved more than 450 gouty arthritis patients for whom the standard anti-inflammatory therapies, non-steroidal anti-inflammatory drugs (NSAIDs) or colchicine, were inadequate or inappropriate(1,2). Results will be presented for the first time at the 2011 European League Against Rheumatism (EULAR) Congress in London.

"Patients describe gouty arthritis as agonizingly painful," said Naomi Schlesinger, MD, Associate Professor of Medicine, Chief, Division of Rheumatology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson University Hospital. "This new research demonstrates that ACZ885, which inhibits interleukin-1 beta, effectively treated and extended the time to new gouty arthritis attacks, thus reducing new attacks in gouty arthritis patients for whom many standard therapies were inadequate or inappropriate."

Both trials used an internationally recognized pain scale to measure differences in pain 72 hours after treatment, and found ACZ885 reduced pain by an additional 11.4 millimeters (mm) (p=0.0005) in one study and 9.8 mm in the other (p=0.0018), compared to TA(1). ACZ885 also significantly reduced the risk of suffering a new gouty arthritis attack within three months compared to TA, by 55% in one study (p=0.0014) and 68% in the other (p<0.0001)(2).

Gouty arthritis, commonly referred to as gout, is a serious, chronic and progressive inflammatory disease that affects up to 8.3 million Americans(3,5). The most common form of inflammatory arthritis in adults,
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... MENLO PARK, Calif. , Aug. 27, ... developer of advanced cancer therapeutics , will be ... Rodman & Renshaw Global Investment Conference, sponsored by ... place Tuesday, September 9th at 2:55 p.m. EDT in ... York Palace Hotel in New York City ...
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com announces that ... its catalogue: Global Orthopedic Soft Tissue ... http://www.reportlinker.com/p02316671/Global-Orthopedic-Soft-Tissue-Repair-Devices-Market-2014-2018.html About Orthopedic Soft ... mass of cells that connect, support, or surround ... tissues such as tendons, ligaments, cartilage, fascia, and ...
(Date:8/27/2014)... , Aug. 27, 2014   Los Angeles orthodontics ... AcceleDent® Aura to patients who want to make their ... available at the OrthoSpaceship, all patients have a powerful ... This system can be used by most patients with ... of progress by using the AcceleDent® Aura system for ...
Breaking Medicine Technology:DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 2DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 3DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 3Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 5Los Angeles Orthodontist, Dr. Isaac Hakim, is Now Offering AcceleDent Aura 2
(Date:8/27/2014)... New York (PRWEB) August 27, 2014 ... filed in U.S. courts on behalf of women who ... uterine morcellation, Bernstein Liebhard LLP reports. According to court ... on August 18th in the U.S. District Court, Northern ... patient who claims the use of a power morcellator ...
(Date:8/27/2014)... Austin, TX (PRWEB) August 27, 2014 Picture, ... no, not Holmes and Watson but more of a Mr. ... Glenn Davis, in terms of personalities and world view. This ... The University of Texas at Austin, and Mr. Outside was ... professor’s family physician, his new girlfriend, and a gaggle of ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 When Jagger was ... call from his mother; one that he credits as one ... His mom had news that she could set him up ... people with disabilities. Jagger took that job, and he has ... Throughout these past two decades, he also worked in school ...
(Date:8/27/2014)... 2014 The newest Abington Health ... September 8, 2014. This new 15,000 square foot, $5 ... primary care practices and walk-in laboratory services. ... exciting endeavor for Abington Health as the healthcare landscape ... Health. “Establishing a location in Lower Gwynedd allows us ...
(Date:8/27/2014)... By Amy Norton ... -- People who take part in clinical trials of new ... typical heart patient, a new study confirms. Experts said ... of the American Medical Association , aren,t surprising -- but ... trials are enrolling a more select patient population that is ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 4Health News:UW Rankin Self-Publishes Debut Novel, Sublimity: Perchance to Dream, A Speculative Science Mystery 2Health News:Fitness on the Go Expands into Liberty Village, City Place and Harbourfront Communities 2Health News:Fitness on the Go Expands into Liberty Village, City Place and Harbourfront Communities 3Health News:Fitness on the Go Expands into Liberty Village, City Place and Harbourfront Communities 4Health News:Abington Health Opens New Health Center in Lower Gwynedd 2Health News:Heart Studies Don't Reflect Real-World Patients, Study Finds 2Health News:Heart Studies Don't Reflect Real-World Patients, Study Finds 3
... , , , ... 22, 2010 , Forterus, Inc. (Pink Sheets: FTER) announced its results ... CEO, stated, "This has been a transformational year for Forterus and ... believe we have a strong foundation from which to grow our ...
... , Jan. 23 Following the announced end of search ... international aid agency Oxfam said: , "The end of search and rescue ... the survivors is the priority now. , "Hundreds of thousands who lost ... latrines to contain the spread of disease. They need shelter and simple ...
... less, MRI scans show , SATURDAY, Jan. 23 (HealthDay News) ... have less activity in the frontal lobes of their brain, ... activate a portion of your frontal lobes, the more accurate ... yourself as desirable or better than your peers, the less ...
... (PHILADELPHIA) People who are in car crashes ... other injuries at nights or on weekends do not ... disparities as patients who suffer heart attacks, strokes, cardiac ... according to new research from the University of Pennsylvania ...
... 2010 A new American Cancer Society report outlines 21 challenges ... of issues to be addressed and expertise needed to reduce ... low- and middle-income nations that are the target of the ... will appear in the January/February issue of CA: A ...
... is one of the ten most disabling diseases in the ... financial burden on health services as average life expectancy increases. ... nearly 27 million Americans or 12.1% of the adult population ... 2001 study showed that the disease costs US health services ...
Cached Medicine News:Health News:Forterus Announces Fiscal Year 2009 Financial Results 2Health News:Forterus Announces Fiscal Year 2009 Financial Results 3Health News:Forterus Announces Fiscal Year 2009 Financial Results 4Health News:Oxfam Relief Efforts Continue In Haiti 2Health News:Self-Image Linked to Activity in Frontal Lobe of Brain 2Health News:Trauma patients safe from mortality risks associated with so-called 'weekend effect' 2Health News:Trauma patients safe from mortality risks associated with so-called 'weekend effect' 3Health News:Global tobacco report outlines 21 challenges for 21st century 2Health News:Global tobacco report outlines 21 challenges for 21st century 3Health News:Cartilage repair can improve life, ease burden on health services 2
This double-up gel dryer system, 200-240 V, includes 2 Model 583 gel dryers, HydroTech™ vacuum pump, and double-up rack....
The GelAir™ dryer is a component of the GelAir drying system. Supplied as a 230 V, 50 Hz gel drying oven....
... is an electrophoresis gel vacuum dryer that removes ... these gels onto cellophane or filter paper for ... which heat gels from above. The drying surface ... unit includes power cord, porous gel support, transparent ...
Capable of producing up to 500 volts and 500 milliamps, this power supply is ideal for PAGE, SDS-PAGE, DNA or RNA submarine gels as well as all types of small format transfer apparatus....
Medicine Products: